Open-Label Single Dose Pilot Study to Assess Safety, Tolerability and Pharmacokinetics of Risperidone Extended Release Capsules in Patients with Schizophrenia, Schizoaffective Disorder or Bipolar 1 Disorder
Latest Information Update: 17 Jun 2020
At a glance
- Drugs Risperidone (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Lyndra
Most Recent Events
- 11 Jun 2020 According to a Lyndra media release, enrollment and dosing in this trial has been completed.
- 11 Jun 2020 Status changed from not yet recruiting to active, no longer recruiting, according to a Lyndra media release.
- 14 Nov 2019 New trial record